



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : SARAH LALDINTLUANGI
ASSISTANT DIRECTOR (FOOD & DRUGS)
Sr. CMO Office
SERCHHIP-796181
SERCHHIP
2. Serial No. and date of Inspector's memorandum : 014/IPA/2024 , Date: 27-NOV-2024
3. Number of Sample : --
4. Date of receipt : 26-DEC-2024
5. Names of drugs purporting to be contained in the sample : Cetirizine Hydrochloride Tablets IP 10 mg (Cetispan)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024-25/1702	GUW/LS/2024-25/1722	CNA23003	Dec-2023	Nov-2025	DANISH HEALTH CARE (P) LTD., 76/27-29, Industrial Estate, Maxi Road, UJJAIN 456 010, INDIA

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] Specimen impression of the seal received from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 10-Feb-2025 To 14-Feb-2025

COMPOSITION : Each film coated tablet contains:
Cetirizine Hydrochloride IP 10 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, elongated, bi-convex, film coated tablet having scored on one side in blister strip.	NA
2	Identification	Gives positive test for Cetirizine Hydrochloride.	NA
3	Average weight	0.16716 g	NA
4	Dissolution	Complies.	NLT 75 %

say

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Cetirizine Hydrochloride	9.81 mg/Tablet	10 mg/Tablet	98.1	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conforms to I.P. with respect to the above tests only.

Date: 14-FEB-2025



**GOVERNMENT ANALYST
Amar Jyoti Chamuah
Government Analyst
R.D.T.L., Guwahati-22**

END OF REPORT

